Phaseline

Targets › AVPR2

AVPR2 (Vasopressin V2 receptor): drug programs, companies and trials

8 programs from 7 companies in 21 trials: 9 Phase 3, 5 Phase 4, 4 Phase 1, 3 Phase 2; Metabolic and endocrine, Genitourinary, Gastroenterology; next expected readout Jan 2027.

G protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal water reabsorption. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, P30518)

Open in Phaseline: the race on AVPR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TiohundraVasopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Vasoplegic Syndrome of Cardiac Surgery; Retained Products of Conception; Shock …Jan 2027
Hamilton Health Sciences CorporationDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Chronic Kidney DiseasesFeb 2027
Assistance Publique - Hôpitaux de ParisDesmopressin Acetate
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3HyponatremiaDec 2027
OtsukaTolvaptan (OPC-41061)
Vasopressin V2 receptor antagonist
AVPR2Phase 3Autosomal Recessive Polycystic Kidney (ARPKD)Dec 2028
Medical University of BialystokDesmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 3Kidney Biopsy–
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Desmopressin
Vasopressin receptor agonist
AVPR2, AVPR1A, AVPR1BPhase 2Cushing SyndromeOct 2028
OtsukaNDI-5001
Vasopressin V2 receptor agonist
AVPR2Phase 1Diabetes InsipidusAug 2027
PharmaINTerlipressin (PHIN-214)
Vasopressin V1 receptor binding agent; Vasopressin V2 receptor binding agent
AVPR1A, AVPR1B, AVPR2Phase 1Cirrhosis, Liver–

Conditions

Sepsis (2) Septic Shock (2) Hyponatremia (1) Kidney Biopsy (1) Cushing Syndrome (1) Chronic Kidney Diseases (1) Diabetes Insipidus (1) Cirrhosis, Liver (1) Autosomal Recessive Polycystic Kidney (ARPKD) (1) Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial (1) Vasoplegic Syndrome of Cardiac Surgery (1) Retained Products of Conception (1)

Modalities

small molecule (8)

Companies

Otsuka (2) Assistance Publique - Hôpitaux de Paris (1) Medical University of Bialystok (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Hamilton Health Sciences Corporation (1) PharmaIN (1) Tiohundra (1)

Related targets

AVPR1A (6) AVPR1B (6)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.